CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04642482
NCT04642482Phase 4Completed

The Effect of Synbiotic on Intestinal Microbiota and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) on Obesity

Hasanuddin University·interventional·Posted Nov 24, 2020·Updated Nov 24, 2020

In Brief

A Phase 4 clinical trial evaluating Synbiotic (Rillus) and Placebo for Obesity and Insulin Resistance. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Background : There is a plausible relationship between microbial gut and insulin resistance. Intervention to prevent insulin resistance by modifying the microbial gut has been proposed but limited studies demonstrates the expected impact. One of the possible way to manipulate the microbial gut is the administration of synbiotic (prebiotic and probiotic). Objective : This study aim to address the impact of synbiotic administration to the microbial gut and insulin resistance. Brief Methodology : A Quasi Experimental study with multiple arms is conducted to healthy participants. All subjects will undergo a microbial gut taxonomic analysis using faecal sample and blood examination to determine the insulin resistance status (using Homeostatic Model Assessment for Insulin Resistance/HOMA-IR approach). Synbiotic will be given to intervention arm and active comparator will use maltodextrin. Repeated measurement will be conducted after 8 weeks and 12 weeks from the day of administration. Hypothesis : A superiority trial hypothesis is applied, assuming that the synbiotic group will demonstrates higher variety of microbial gut and lower HOMA-IR level

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndonesia
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 24, 2020
Enrollment StartSep 24, 2019
Primary CompletionDec 26, 2019
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.6 years ago

Interventions

Synbiotic (Rillus)dietary

Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.

Placebodrug

Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.